Polo‐like kinase 4 inhibitor CFI‐400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity
Hepatology2022Vol. 77(3), pp. 729–744
Citations Over TimeTop 10% of 2022 papers
Cerise Yuen‐Ki Chan, Vincent Wai‐Hin Yuen, David Kung‐Chun Chiu, Chi Ching Goh, Kelsie L. Thu, David W. Cescon, Isabel Soria‐Bretones, Cheuk‐Ting Law, Jacinth Wing‐Sum Cheu, Derek Lee, Aki Pui‐Wah Tse, Kel Vin Tan, Misty Shuo Zhang, Bowie Po‐Yee Wong, Chun‐Ming Wong, Pek‐Lan Khong, Irene Oi‐Lin Ng, Mark R. Bray, Tak W. Mak, Thomas Yau, Carmen Chak‐Lui Wong
Abstract
We show that by targeting a centrosome regulator, PLK4, to activate the cytosolic DNA sensing-mediated immune response, CFI-400945 effectively restrained tumor progression through cell cycle inhibition and inducing antitumor immunity to achieve a durable suppressive effect even in late-stage mouse HCC.
Related Papers
- → Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress(2014)238 cited
- → DNA damage repair and cardiovascular diseases(2010)42 cited
- → Cytotoxicity and mutagenicity of endogenous DNA base lesions as potential cause of human aging(2008)40 cited
- → Cellular Responses to DNA Damage(2017)2 cited
- → The role of progesterone-induced blocking factor (PIBF) in invasion of primary ovarian tumour cells(2017)